Bullboard - Stock Discussion Forum Arch Biopartners Inc V.ARCH

Alternate Symbol(s): ACHFF

Technology Scientific & Technical Instruments

Arch Biopartners Inc. is a late-stage clinical trial company focused on preventing acute kidney injury. The Company is developing a platform of new drugs to prevent inflammation injury in the kidneys, lungs and liver via the dipeptidase-1 (DPEP1) pathway and are relevant for many common injuries and diseases where organ inflammation is an unmet problem. The Company’s lead drug candidate is... see more

Add To Watchlist

TSXV:ARCH - Post Discussion

Arch Biopartners Inc > Probability of Success - 52.8% ( 20 Billion unmet Market)

View:

Post by Riverfolk on Dec 02, 2021 2:02pm

Probability of Success - 52.8% ( 20 Billion unmet Market)

New Clinical Developement Succes Rates 2011-2020 Report

Statistically speaking in the report available above, Arch Biopartners has a 52.8% chance of having a drug make it ot the approval process from the regulator. Given that there is no standard of care for the area of medicine being saught, the odds go up dramattically

PEPTIDES Likelihood of approval

Phase I to Approval - 8%
Phase II to Approval - 15%
Phase III to Approval - 52.8%
NDA/BLA to Approval - 88.1%

With an additional 8 fully patented drug candidates in the library this is beyond exciting as a share holder as Pharma will 100% take notice with Arch is a decade ahead of the game!

166